Low-risk percutaneous coronary interventions without on-site cardiac surgery: two years' observational experience and follow-up.
暂无分享,去创建一个
Farris K. Timimi | D. Holmes | Mandeep Singh | K. Garratt | F. Timimi | H. Ting | D. Wood | Farris K Timimi | J. Cusma | M. A. Kjelsberg | K. T. Cragun | R. Houlihan | Katherine L. Boutchee | Christopher H. Crocker | K. Cragun
[1] D. Wennberg,et al. Relation between operator and hospital volume and outcomes following percutaneous coronary interventions in the era of the coronary stent , 2001 .
[2] David O. Williams,et al. ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary , 2001 .
[3] J. Rumsfeld,et al. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy. , 2000, JAMA.
[4] T. Ryan,et al. Relation between operator and hospital volume and outcomes following percutaneous coronary interventions in the era of the coronary stent. , 2000, JAMA.
[5] A. Jacobs,et al. Percutaneous Coronary Intervention in the Current Era Compared With 1985–1986: The National Heart, Lung, and Blood Institute Registries , 2000, Circulation.
[6] T. Aversano. The Atlantic C-PORT Trial: A Community-Hospital–Based, Prospective, Randomized Trial Comparing Thrombolytic Therapy With Primary , 2000 .
[7] S E Nissen,et al. American College of Cardiology/European Society of Cardiology International Study of Angiographic Data Compression Phase I: The effect of lossy data compression on recognition of diagnostic features in digital coronary angiography. , 2000, Journal of the American College of Cardiology.
[8] Marshall A. Lichtman,et al. Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961 , 2000 .
[9] R. Califf,et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. , 1999, Circulation.
[10] F. Fedele,et al. Primary angioplasty for the treatment of acute myocardial infarction: experience at two community hospitals without cardiac surgery. , 1999, Journal of the American College of Cardiology.
[11] S. Kimmel,et al. ACCF/AHA/SCAI 2007 update of the clinical competence statement on cardiac interventional procedures: A report (Writing Committee to Update the 1998 Clinical Competence Statement on Recommendations for the Assessment and Maintenance of Proficiency in Coronary Interventional Procedures) , 2007 .
[12] T. Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.
[13] S. Kimmel,et al. Recommendations for the Assessment and Maintenance of Proficiency in Coronary Interventional Procedures , 1998 .
[14] Epilog Investigators,et al. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.
[15] D. Smyth,et al. Direct Angioplasty for Myocardial Infarction: One-Year Experience in a Center with Surgical Back-up 220 Miles Away. , 1997, The Journal of invasive cardiology.
[16] Mansfield,et al. Retrospective Comparison of a Strategy of Primary Coronary Angioplasty versus Intravenous Thrombolytic Therapy for Acute Myocardial Infarction in a Community Hospital without Cardiac Surgical Backup. , 1996, The Journal of invasive cardiology.
[17] M. Ayres. Coronary angioplasty for acute myocardial infarction in hospitals without cardiac surgery. , 1995, The Journal of invasive cardiology.
[18] Epic Investigators,et al. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.
[19] W. Weaver,et al. Characteristics of Patients Treated With Direct Angloplasty In the Two Types of Hospital Facilities and In Patients Treated With Thrombolytic Therapy in the Same Group of Hospitals No Thrombolytic On-Site Direct Angloplasty Drug Surgery On-Site Surgery All Treatment , 2005 .
[20] S. Phillips,et al. Coronary angioplasty for acute myocardial infarction in a hospital without cardiac surgery. , 1993, Texas Heart Institute journal.
[21] J. Vogel. Angioplasty in the patient with an evolving myocardial infarction: With and without surgical backup , 1992, Clinical cardiology.
[22] D. Holmes,et al. Percutaneous transluminal coronary angioplasty: current status and future trends. , 1986, Mayo Clinic proceedings.